Bifogade filer
Kurs & Likviditet
Kalender
2025-02-11 | Bokslutskommuniké 2024 |
2024-11-12 | Kvartalsrapport 2024-Q3 |
2024-08-06 | Kvartalsrapport 2024-Q2 |
2024-05-22 | Ordinarie utdelning RESP 0.00 SEK |
2024-05-21 | Årsstämma 2024 |
2024-05-21 | Kvartalsrapport 2024-Q1 |
2024-02-13 | Bokslutskommuniké 2023 |
2023-11-14 | Kvartalsrapport 2023-Q3 |
2023-08-08 | Kvartalsrapport 2023-Q2 |
2023-05-17 | Ordinarie utdelning RESP 0.00 SEK |
2023-05-16 | Kvartalsrapport 2023-Q1 |
2023-05-16 | Årsstämma 2023 |
2023-02-07 | Bokslutskommuniké 2022 |
2022-11-08 | Kvartalsrapport 2022-Q2 |
2022-08-30 | Kvartalsrapport 2022-Q1 |
2022-06-10 | Ordinarie utdelning RESP 0.00 SEK |
2022-06-09 | Årsstämma 2022 |
2022-05-13 | Bokslutskommuniké 2021 |
2022-05-03 | Ordinarie utdelning RESP 0.00 SEK |
2022-03-14 | Extra Bolagsstämma 2022 |
2021-11-10 | Kvartalsrapport 2021-Q3 |
2021-08-06 | Kvartalsrapport 2021-Q2 |
2021-06-10 | Årsstämma 2021 |
2021-05-28 | Ordinarie utdelning RESP 0.00 SEK |
2021-05-27 | Kvartalsrapport 2021-Q1 |
2021-02-03 | Bokslutskommuniké 2020 |
2020-11-04 | Kvartalsrapport 2020-Q3 |
2020-08-25 | Kvartalsrapport 2020-Q2 |
2020-05-20 | Ordinarie utdelning RESP 0.00 SEK |
2020-05-19 | Årsstämma 2020 |
2020-05-19 | Kvartalsrapport 2020-Q1 |
2020-02-04 | Bokslutskommuniké 2019 |
2019-11-07 | Kvartalsrapport 2019-Q3 |
2019-08-30 | Kvartalsrapport 2019-Q2 |
2019-05-29 | Ordinarie utdelning RESP 0.00 SEK |
2019-05-28 | Kvartalsrapport 2019-Q1 |
2019-05-28 | Årsstämma 2019 |
2019-02-05 | Bokslutskommuniké 2018 |
2018-11-07 | Kvartalsrapport 2018-Q3 |
2018-08-28 | Kvartalsrapport 2018-Q2 |
2018-05-16 | Ordinarie utdelning RESP 0.00 SEK |
2018-05-15 | Kvartalsrapport 2018-Q1 |
2018-05-15 | Årsstämma 2018 |
2018-02-06 | Bokslutskommuniké 2017 |
2017-11-07 | Kvartalsrapport 2017-Q3 |
2017-08-29 | Kvartalsrapport 2017-Q2 |
2017-05-03 | Ordinarie utdelning RESP 0.00 SEK |
2017-05-02 | Årsstämma 2017 |
2017-05-02 | Kvartalsrapport 2017-Q1 |
2017-02-08 | Bokslutskommuniké 2016 |
2016-11-11 | Kvartalsrapport 2016-Q3 |
2016-08-01 | Kvartalsrapport 2016-Q2 |
2016-05-03 | Ordinarie utdelning RESP 0.00 SEK |
2016-05-02 | Årsstämma 2016 |
2016-05-02 | Kvartalsrapport 2016-Q1 |
2016-02-18 | Bokslutskommuniké 2015 |
2015-11-04 | Kvartalsrapport 2015-Q3 |
2015-08-06 | Kvartalsrapport 2015-Q2 |
2015-04-30 | Ordinarie utdelning RESP 0.00 SEK |
2015-04-29 | Kvartalsrapport 2015-Q1 |
2015-04-29 | Årsstämma 2015 |
2015-02-27 | Bokslutskommuniké 2014 |
2014-10-30 | Kvartalsrapport 2014-Q3 |
2014-07-30 | Kvartalsrapport 2014-Q2 |
2014-05-06 | Ordinarie utdelning RESP 0.00 SEK |
2014-05-05 | Årsstämma 2014 |
2014-05-05 | Kvartalsrapport 2014-Q1 |
2014-02-28 | Bokslutskommuniké 2013 |
2013-11-07 | Kvartalsrapport 2013-Q3 |
2013-08-21 | Kvartalsrapport 2013-Q2 |
2013-05-21 | Ordinarie utdelning RESP 0.00 SEK |
2013-05-20 | Kvartalsrapport 2013-Q1 |
2013-05-20 | Årsstämma 2013 |
2013-02-28 | Bokslutskommuniké 2012 |
2012-11-30 | Kvartalsrapport 2012-Q3 |
2012-08-31 | Kvartalsrapport 2012-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Bioteknik |
Respiratorius announces decision from the Patent Trial and Appeal Board (PTAB) at the American Patent Office (USPTO) regarding the patent application for the formulation of VAL001. The PTBA has reversed all rejections of the examiner to both individual claims and the decision to reject the patent application, which means that the examiner must reopen the application.
In addition to reversing the examiner's decision, the Patent Trial and Appeal Board does not point out any new rejections, which is considered as the examiner's ability to raise new rejections to the patent application is limited.
The patent application is Respiratorius' first concerning formulation and claims a new oral formulation of sodium valproate for the pre-treatment of cancer. The priority date for the patent application is April 21, 2016, and is valid for at least 20 years from the priority date, which if approved provides market exclusivity during this period. The corresponding application was approved in Japan in 2022 and in Canada in 2023.
This disclosure contains information that Respiratorius is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-04-2024 14:44 CET.
President Respiratorius AB
+46 709-22 41 40
johan.drott@respiratorius.com